SCHEMBL19867053

SCHEMBL19867053

CC(O)C(NC(=O)N[C@@H](CC(N)=O)c1nc(-c2nc3ccccc3[nH]2)no1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD274 Q9NZQ7 4/20 0.57
VSIR Q9H7M9 3/20 0.57
PDCD1LG2 Q9BQ51 2/20 0.41
PDCD1 Q15116 1/20 0.40
KDM4E B2RXH2 4/20 0.37
HTT P42858 2/20 0.37
MAPT P10636 1/20 0.37
PAK4 O96013 1/20 0.37
CDK2 P24941 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.36
MAPK1 P28482 1/20 0.36
ALDH1A1 P00352 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
HPGD P15428 2/20 0.35
LMNA P02545 2/20 0.35
PKM P14618 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18077986 1.00 CD274 (0.57) CD274VSIRPDCD1LG2PDCD1KDM4E
SCHEMBL18078744 0.84 CD274 (0.48) CD274VSIRPDCD1LG2PDCD1KDM4E
SCHEMBL19866397 0.84 CD274 (0.48) CD274VSIRPDCD1LG2PDCD1KDM4E
SCHEMBL18077945 0.83 VSIR (0.63) CD274VSIRPDCD1LG2PDCD1LMNA
SCHEMBL19867031 0.83 VSIR (0.63) CD274VSIRPDCD1LG2PDCD1LMNA
SCHEMBL19450457 0.83 VSIR (0.63) CD274VSIRPDCD1LG2PDCD1LMNA
SCHEMBL18077944 0.81 VSIR (0.61) CD274VSIRPDCD1LG2PDCD1KDM4E
SCHEMBL19867037 0.81 VSIR (0.61) CD274VSIRPDCD1LG2PDCD1KDM4E
SCHEMBL19981242 0.81 FLT3 (0.40) KDM4EHTTMAPTPAK4CDK2
SCHEMBL19867090 0.78 CD274 (0.61) CD274VSIRPDCD1LG2PDCD1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180044329-A1 3-SUBSTITUTED-1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2018-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044329-A1 3-SUBSTITUTED-1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS PDCD1, CD274, PDCD1LG2 CD274 2/4885VSIR 2158/4885PDCD1LG2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.